TTK and cancer: TTK inhibitors BAY 1161909 and BAY 1217389 in combination with antimitotic cancer drugs achieve obvious enhancement effects over paclitaxel or TTK inhibitor monotreatment through abrogating SAC in a variety of xenograft models [32].